The Internet Economy; Biotech Style
Executive Summary
Euphoria reigned at the Chase H&Q annual health care conference. Biotechs that seemed unable to buy an audience last year presented to rooms so crowded that breathing itself was difficult. To some extent, the biotechs, particularly the genomics companies, were benefiting from the rotation of investors out of the Internet. But something else was afoot: the Internet way of valuing companies had come to biotech. In particular, the biotechs are no longer being valued according to some basic earnings model, but--like the Internet plays--on their potential to dominate their niches, and then use their financial power, as reflected in their share prices, to consolidate to themselves other and harder assets.
You may also be interested in...
China Re-Infection Case Ignites Antibody Durability Debate
Amid a case of re-infection of a vaccinated healthcare worker in western China’s Xi’an city, and ongoing debate over domestic vaccines' efficacy, increasing attention is being paid in China to raising inoculation rates for COVID-19 and moving towards herd immunity.
Medtronic Addresses Diabetes Care Disparities With New Equity Initiatives
The company announced new research investments and partnerships with the American Diabetes Association and the T1D Exchange to address racial disparities in treatment of diabetes.
QUOTED. 19 April 2021. Jeff Shuren & William Maisel
Two top officials in the US FDA’s device center are warning of delays in the agency’s review of submissions for new products that aren’t directly tied to the coronavirus pandemic.